AOP Orphan Pharmaceuticals AG obtains Thromboreductin® registrations in Central Europe
Vienna, Austria (ots) - AOP Orphan Pharmaceuticals, manufacturer and product developer of Thromboreductin®, announces that it has achieved its intermediate goal to make Thromboreductin® available in the European Union by means of an ambitious GCP compliant clinical trial programme. Thromboreductin is the first Anagrelide containing medicinal product approved ...
plus